importance of vasculature in growth of all types of tissue
tumour genesis
one key aspect is that the genetics of the cancer cells are not controlling how this tissue morphology is set up.
- So actually what tumors have to do is to recruit blood vessels to them and to remodel that tumor microenvironment
- and they essentially designing their own vasculature as the tumor grows
what makes up the vasculature
blood vascular endothelial cells
the cell types that form the blood vessels
when endothelial cells are activated they start to deform the morphology and form a curved shape that curves around and joins with other endothelial cells - forms a tube
And what’s really important about this structure is these intercellular cleft - these connections between adjacent endothelial cells
- So these are formed by tight junctions, lots of adhesion proteins in these intercellular connections, and it’s really key for how these endothelial cells could control the passage of various molecules and cells out of the bloodstream. Into the surrounding interstitial tissue
how do tumour endothelial cells differ from normal endothelial cells
pericytes
lymphatic endothelial cells
how close do tumour cells need to be to blood vessels
if tumor cells are within that 200 microns of a capillary or a blood vessel, They appear to grow quite well Whereas Pathologists tended not to see well growing tumors that were further than about 0.2 millimeters from a blood vessel.
why do tumours need to be so close to a vessel
in close proximity to either vessel, we’ve got high levels of oxygen.
- So this is because there’s oxygen diffusing through the capillary endothelial cells and
is able to oxygenate that close environment to the blood vessel.
But as you move further away from the vessel in either direction, you get to this point that is quite far away from the vessel and the oxygen pressure has dropped dramatically.
- So oxygen is not able to diffuse through to this distance as well.
- And we get this region of hypoxia at some distance from the blood vessels.
- going to impair cell growth in general and tumor cell growth as well.
hypoxic and anoxic environments
is hypoxic and anoxic environments Starts to trigger a process of necrosis and this is where you can see all the cells collapsing in on themselves. The tissue is collapsing in on itself and dying.
how can tumour cells try to avoid this hypoxic environment and continue to grow - 1
-early in tumour progression, clusters of tumour cells grow to 0.2 mm
- as the tumor starts to grow and there’s insufficient vasculature in that environment, Then we get we start to get hypoxia - trigger p53 dependent apoptosis.
- to try and counteract this tumour cells will secrete vascular endothelial growth factor vegf.
- when secreted, The ECM that is surrounding all the cell’s is able to tether that growth factor to the ECM.
And when vegf is sequestered into the Matrix like that other cells aren’t able to detect the vegf. It’s unable to stimulate any processes
how can tumour cells try to avoid this hypoxic environment and continue to grow - 2
then tumor cells will acquire the ability to recruit other cells and we call this an angiogenic switch + Generally, these are inflammatory cells
- when the tumor cells are able to recruit these into the TME, These inflammatory cells then secrete An enzyme that can degrade The extracellular Matrix.
- a protease called Matrix metalloproteinase 9
- when MMP chops up the extracellular Matrix into smaller parts the vegf that was locked into the Matrix can then become released
- And vegf can then stimulate the recruitment of endothelial cells and activation of endothelial cells to start to change their morphology to curve around to join it with other endothelial cells and form these capillary vessels.
- You’ve then got angiogenesis in the local tumor microenvironment
growth factor signalling in tumorigenesis
there are several families of growth factor receptors.
- They have extracellular domains that bind the growth factor.
- They have intracellular tyrosine kinase domain that triggers phosphorylation events and cell signaling events intracellularly.
- many of these are important in tumor Genesis
- platelet-derived growth factor pdgf and Vegf receptor
vascular endothelial growth factor
so what happens once the vegf has been secreted and then released from the
Matrix
endothelial cells detect these growth factors such as vegf
- the vegf triggers the endothelial cells to proliferate so there’s more endothelial cells and secondly to deform to form these cylindrical walls to form Intercellular cleft with other endothelial cells to form these cylinders
- capillaries then become addicted to high concentrations of growth factors like vegf. So they are always trying to move up the concentration gradient towards higher concentrations of vegf.
- so that allows the capillaries to develop and grow towards these high vegf concentrations.
- capillaries can penetrate through existing tissues to try and get to these higher concentrations of growth factor.
tumour capillaries
often in tumors capillaries are much wider than normal capillaries
The organization early on is quite neat and branched whereas towards the end as the tumor grows larger and larger, There’s much more haphazard arrangement of capillaries
leakiness in tumour capillaries
growth factor PDGF
the growth factor pdgf is also important for controlled capillary formation.
- can also go wrong in cancer.
- in a normal situation when you’ve got your capillary forming These endothelial cells can secrete pdgf b and the pdgf can fall into the local extracellular Matrix and pericytes in the area can detect this pdgf and that brings them towards the endothelial cells and then they’re able to bind to the endothelial cells and support the capillary structure.
- in cases where there are mutations in pdgf b, certain mutations mean that this pdgf can’t be retained in the local extracellular Matrix and it just diffuses away into the tissue. So there’s no local concentration of pdgf anymore and pericytes are unable to be recruited as efficiently
○ and so what that means is you don’t get the support on the capillary.
high intratumoral hydrostatic pressure
what does high intratumoral hydrostatic pressure cause
high fluid pressure in the tumour complicates administration of anti-cancer drugs as they are not transferred down the pressure gradient from the circulation to the interstitial spaces of the tumour: drugs stay in the circulation
strategies to reduce this hydrostatic pressure
one example leans on the fact that excess vegf is causing this permeability of the blood vessels.
- in a normal tissue, there’s a normal flow of blood through the tissue and as the tumor starts to grow larger and larger this blood supply becomes less regular and less efficient, The capillaries are truncated and dysregulated as the tumor gets bigger and There aren’t enough capillary, So there’s hypoxic regions of the tumor
- in mice with tumours, treatment with anti - VEGF monoclonal antibodyy returns vasculature to a normal configuration and reduces interstitial tumour pressure
anti - VEGF monoclonal antibody treatment - importance of balance
this therapeutic approach has to be keenly balanced.
- Because if there is not enough vegf therapy, then there will be no change to that irregular and inefficient blood flow through the tumor.
- But it there is too much suppression of vegf signaling then actually there won’t be enough blood flowing through the tumor so theres more hypoxia
○ And then hypoxia can actually induce invasiveness of cancer cells.
○ So the cancer cells will start to invade through and away from the tumor and start to trigger metastatic Cascade.
to achieve normalisation, the dosing is important, and the timing of the drug treatments are important - must be optimised according to each patient
cellular senescence
a typically irreversible form of proliferative arrest
- senescent cells remain metabolically active but lose the ability to re enter the active cell cycle
- induced by nutrient deprivation, DNA damage, organelle damage, oncogene-induced signalling
- characterised by presence of markers of cell cycle arrest (e.g. CDK inhibitors p15, p16, p21)
- characterised by absence of the proliferation marker Ki67
replicative senescence